109 related articles for article (PubMed ID: 7557642)
1. Effects of a dopamine antagonist (metoclopramide) on the release of beta-endorphin, ACTH and cortisol in hyperprolactinemic-amenorrheic women.
Seki K; Mitsui C; Nagata I
Gynecol Obstet Invest; 1995; 40(1):42-5. PubMed ID: 7557642
[TBL] [Abstract][Full Text] [Related]
2. Dopamine infusion enhances the adrenocorticotropic hormone and cortisol response to metoclopramide in hyperprolactinemic patients but not in normal subjects.
Moro M; Maraschini C; Cavagnini F
Gynecol Endocrinol; 1997 Jun; 11(3):155-62. PubMed ID: 9209895
[TBL] [Abstract][Full Text] [Related]
3. Responses of growth hormone to metoclopramide in normal women and amenorrheic women with or without hyperprolactinemia.
Seki K; Kato K
Endocrinol Jpn; 1986 Oct; 33(5):721-5. PubMed ID: 3830074
[TBL] [Abstract][Full Text] [Related]
4. Parallelism in the luteinizing hormone responses to opioid and dopamine antagonists in hyperprolactinemic women with pituitary microadenoma.
Seki K; Kato K; Shima K
J Clin Endocrinol Metab; 1986 Nov; 63(5):1225-8. PubMed ID: 3760121
[TBL] [Abstract][Full Text] [Related]
5. Corticotrophin and vasopressin responses to metoclopramide in patients with hypothalamic amenorrhoea.
Seki K; Kato T; Sekiya S
Clin Endocrinol (Oxf); 1997 Feb; 46(2):203-7. PubMed ID: 9135703
[TBL] [Abstract][Full Text] [Related]
6. Effects of thyrotropin-releasing hormone and metoclopramide on PRL secretion in normally cycling and amenorrheic alcoholic women.
Vescovi PP; Coiro V
Drug Alcohol Depend; 1997 Apr; 45(1-2):115-9. PubMed ID: 9179513
[TBL] [Abstract][Full Text] [Related]
7. Differences in the opioid control of luteinizing hormone secretion between pathological and iatrogenic hyperprolactinemic states.
Petraglia F; De Leo V; Nappi C; Facchinetti F; Montemagno U; Brambilla F; Genazzani AR
J Clin Endocrinol Metab; 1987 Mar; 64(3):508-12. PubMed ID: 2880862
[TBL] [Abstract][Full Text] [Related]
8. Cortisol secretion in patients with normoprolactinemic amenorrhea.
Boesgaard S; Hagen C; Andersen AN; Djursing H; Fenger M
Acta Endocrinol (Copenh); 1988 Aug; 118(4):544-50. PubMed ID: 2840794
[TBL] [Abstract][Full Text] [Related]
9. Catecholamines and pituitary-function. V. Effect of low-dose dopamine infusion on basal and gonadotropin-releasing hormone stimulated gonadotropin release in normal cycling women and patients with hyperprolactinemic amenorrhea.
Nicoletti I; Ambrosi F; Giammartino C; Fedeli L; Mannarelli C; Filipponi P
Horm Metab Res; 1986 Jul; 18(7):479-84. PubMed ID: 3091473
[TBL] [Abstract][Full Text] [Related]
10. Functional evaluation of the adenohypophysis with metoclopramide in hyperprolactinemic-amenorrheic women in relation to radiological findings on the sella turcica.
Seki K; Uesato T; Kato K; Shima K
Endocrinol Jpn; 1984 Dec; 31(6):733-9. PubMed ID: 6532792
[TBL] [Abstract][Full Text] [Related]
11. Twenty-four hour secretory pattern of thyroid-stimulating hormone in hyperprolactinemic women with pituitary microadenoma.
Seki K; Uesato T; Kato K; Shima K
Endocrinol Jpn; 1985 Jun; 32(3):369-73. PubMed ID: 4042992
[TBL] [Abstract][Full Text] [Related]
12. The effect of naloxone and metoclopramide on the secretion of luteinizing hormone in a hyperprolactinemic hypogonadotropic postmenopausal woman.
Verhelst J; Beckers A; Abs R
Fertil Steril; 1995 Nov; 64(5):969-71. PubMed ID: 7589643
[TBL] [Abstract][Full Text] [Related]
13. Variability of cortisol and adrenocorticotropic hormone responses to metoclopramide during the menstrual cycle.
Seki K
Gynecol Obstet Invest; 1989; 27(4):201-3. PubMed ID: 2545573
[TBL] [Abstract][Full Text] [Related]
14. The role of endogenous opiates in the mechanism of inhibited luteinizing hormone (LH) secretion in women with anorexia nervosa: the effect of naloxone on LH, follicle-stimulating hormone, prolactin, and beta-endorphin secretion.
Baranowska B; Rozbicka G; Jeske W; Abdel-Fattah MH
J Clin Endocrinol Metab; 1984 Sep; 59(3):412-6. PubMed ID: 6086696
[TBL] [Abstract][Full Text] [Related]
15. Male patients with paranoid schizophrenia have greater ACTH and cortisol secretion in response to metoclopramide-induced AVP release.
Walsh P; Spelman L; Sharifi N; Thakore JH
Psychoneuroendocrinology; 2005 Jun; 30(5):431-7. PubMed ID: 15721055
[TBL] [Abstract][Full Text] [Related]
16. Metoclopramide effect on serum prolactin LH and FSH in patients with polycystic ovary syndrome.
Prelević GM; Würzburger MI; Perić LA
J Endocrinol Invest; 1988 Apr; 11(4):255-9. PubMed ID: 3137253
[TBL] [Abstract][Full Text] [Related]
17. Clinical use of metoclopramide test in the diagnosis of women with hyperprolactinemia.
Vázquez-Matute L; Canales ES; Alger M; Zárate A
Horm Res; 1979; 10(4):207-12. PubMed ID: 571836
[TBL] [Abstract][Full Text] [Related]
18. Pituitary-adrenocortical response to metoclopramide in patients with acromegaly and prolactinoma: a clinical evaluation of catecholamine-mediated adrenocorticotropin secretion.
Nishida S; Matsuki M; Adachi N; Horino M; Yoneda M; Endoh M; Oyama H; Kikuoka M; Otsuka R; Ishii R
J Clin Endocrinol Metab; 1987 May; 64(5):995-1001. PubMed ID: 3031125
[TBL] [Abstract][Full Text] [Related]
19. Effects of prolactin and estrogen deficiency in amenorrheic bone loss.
Klibanski A; Biller BM; Rosenthal DI; Schoenfeld DA; Saxe V
J Clin Endocrinol Metab; 1988 Jul; 67(1):124-30. PubMed ID: 3379129
[TBL] [Abstract][Full Text] [Related]
20. Catecholamines and pituitary function. I. Effects of catecholamine synthesis inhibition and subsequent catecholamine infusion on gonadotropin and prolactin serum levels in normal cycling women and in women with hyperprolactinemic amenorrhea.
Nicoletti I; Filipponi P; Sfrappini M; Fedeli L; Petrelli S; Gregorini G; Santeusanio F; Brunetti P
Horm Res; 1984; 19(3):158-70. PubMed ID: 6425187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
